论文部分内容阅读
AIM:To determine the efficacy of adjuvant chemotherapy for gastric cancer in clinical practice,a retrospective analysis was conducted in a high-volume Chinese cancer center.METHODS:Between November 1995 and June 2007,a total of 423 gastric or esophagogastric adenocarcinoma patients who did(Arm A,n=300)or did not(Arm S,n=123)receive radical gastrectomy followed by postoperative chemotherapy were enrolled in this retrospective analysis.In Arm A,monotherapy(fluoropy rimidines,n=25),doublet(platinum/fluoropyrimidines,n=164),or triplet regimens[docetaxel/cisplatin/5FU(DCF),or modified DCF,epirubicin/cisplatin/5FU(ECF)or modified ECF,etoposide/cisplatin/FU,n=111]were administered.Disease-free survival(DFS)and overall survival(OS)were compared between the two arms.A subgroup analysis was carried out in Arm A.A multivariate analysis of prognostic factors was conducted.RESULTS:Stage?Ⅰ,ⅡandⅢcancers accounted for9.7%,35.7%and 54.6%of the cases,respectively,according to the American Joint Committee on Cancer(AJCC)staging system,7th edition.Only 178(42.1%)patients had more than 15 lymph nodes harvested.Hazard ratio estimates for Arm A compared with Arm S were 0.47(P<0.001)for OS and 0.59(P<0.001)for DFS.The 5-year OS rate was 52%in Arm A vs36%in Arm S(P=0.01);the adverse events in Arm A were mild and easily controlled.Ultimately,73 patients(26.5%)who received doublet or triplet regimens switched to monotherapy with fluoropyrimidines.The OS and DFS did not differ between monotherapy and the combination regimens,however,both were statistically improved in the subgroup of patients who were switched to monotherapy with fluoropyrimidines after doublet or triplet regimens as well as patients who received≥8 cycles of chemotherapy.CONCLUSION:In clinical practice,platinum/fluoropyrimidines with adequate treatment duration is recommended for stageⅡ/Ⅲgastric cancer patients accordingto the 7th edition of the AJCC staging system after curative gastrectomyeven with limited lymphadenectomy.
AIM: To determine the efficacy of adjuvant chemotherapy for gastric cancer in clinical practice, a retrospective analysis was conducted in a high-volume Chinese cancer center. DETHODS: Between November 1995 and June 2007, a total of 423 gastric or esophagogastric adenocarcinoma patients who did (Arm A, n = 300) or did not (Arm S, n = 123) receive radical gastrectomy followed by postoperative chemotherapy were enrolled in this retrospective analysis. In Arm A, monotherapy (fluoropy rimidines, n = 25), doublet / fluoropyrimidines, n = 164), or triplet regimens [docetaxel / cisplatin / 5FU (DCF), or modified DCF, epirubicin / cisplatin / 5FU (ECF) or modified ECF, etoposide / cisplatin / FU, n = 111]. Disease-free survival (DFS) and overall survival (OS) were compared between the two arms. A subgroup analysis was carried out in Arm AA multivariate analysis of prognostic factors was performed .RESULTS: Stage®Ⅰ, ⅡandⅢcancers accounted for9.7% 35.7% and 54.6% of the cases, respectively, according to the American Joint Co. (42.1%) patients had more than 15 lymph nodes harvested. Hazard ratio estimates for Arm A compared with Arm S were 0.47 (P <0.001) for OS and 0.59 (P <0.001) for DFS. The 5-year OS rate was 52% in Arm A vs 36% in Arm S (P = 0.01); the adverse events in Arm A were mild and easily controlled. Ultimately, 73 patients (26.5%) who received doublet or triplet regimens switched to monotherapy with fluoropyrimidines. OS and DFS did not differ between monotherapy and the combination regimens, however, both were statistically improved in the subgroup of patients who switched to monotherapy with fluoropyrimidines after doublet or triplet regimens as well as patients who received ≥ 8 cycles of chemotherapy. CONCLUSION: In clinical practice, platinum / fluoropyrimidines with adequate treatment duration is recommended for stage Ⅱ / Ⅲ gastric cancer patients according to the 7th edition of the AJCC staging system after curative gastrectomyeven with limited lympha denectomy.